Clinical Trial Finder

Inclusion Criteria:

• - Age ≥ 18 years of age.

• - Eastern Cooperative Oncology Group (ECOG)Performance Status of ≤ 2.

• - Measurable tumor by direct visualization requiring surgical resection in the operating room (OR) - Tumor types of origin include gastric, pancreatic, hepatobiliary, colorectal, sarcoma, brain, or breast cancer that may involve the axillary lymph nodes cancers.

Tumors may be primary or metastatic.

• - Subject must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent.

• - Subject must have a skin prick test pre-operatively (at the time of the preoperative visit and after signed informed consent for entry into this clinical trial is given) to determine any sensitivity to fluorescein.

Exclusion Criteria:

• - Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations.

• - Renal dysfunction as defined as a glomerular filtration rate (GFR) < 45.

• - Liver dysfunction as defined by Child-Pugh score > 5, or liver function test (LFT)'s 1.5 x above normal range.

• - Any known allergy or prior reaction to fluorescein or a positive skin prick test to fluorescein.

• - Pregnant or nursing female subjects, determined preoperatively with a urine pregnancy test.

• - Unwilling or unable to follow protocol requirements.

- Any condition which in the investigators' opinion deems the patient unsuitable (e.g., abnormal electrocardiography [EKG], including T wave inversion, elevated T waves, prolonged QRS interval, or conduction blocks) or that requires further work-up (including cardiac echo or stress test) - Any condition that excludes surgical resection as the standard of care for the patient

PRIMARY OBJECTIVE:

• I. To determine the feasibility of performing human intravital microscopy (HIVM) in patients with deep space solid tumors during standard course of surgical resection.

SECONDARY OBJECTIVES:

• I. Compare the microscopic observation of the tumor-associated vessels with normal tissue (e.g. peritoneal surface or normal brain tissue) in each individual subject.

• II. Correlate the microscopic observations of the tumor-associated vessels with pathologic grade of tumor.

• III. To correlate the microscopic observation of the microvasculature with tumor-specific and overall survival.

OUTLINE: Patients receive fluorescein intravenously (IV) and undergo HIVM over 1-2 minutes per field. After completion of study, patients are followed up at 2-3 weeks after surgery.

Arms

Experimental: Arm 1

Determine the feasibility and clinical utility of performing Human Intravital Microscopy (HIVM) in patients with solid tumors during surgical resection.

Interventions

Device: - Diagnostic Microscopy

Undergo Intravital microscopy (IVM), which allows real-time, direct visualization of microscopic blood vessels and calculation of blood flow.

Drug: - Fluorescein Sodium Injection

Given IV as part of IVM procedure